Agenus Inc. (AGEN)

Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

Agenus to Provide Second Quarter 2026 Financial Report and Development Update

Do Options Traders Know Something About Agenus Stock We Don't?

Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026

AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot

Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?

Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer Transcript

Agenus shares surge as company secures up to $340M to advance colon cancer trial

Agenus Stock Soars Over 100% as BATTMAN Takes a Back Seat to ROBBIN

Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing

Agenus shares surge as company secures up to $340M to advance colon cancer trial

VivoPower earns Outperform rating as Noble bets on "power-first" AI strategy

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer

Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026

Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves

Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report?

AGEN Early Access Revenues Signal a New Path Ahead of Approval